Option Care Health, Inc. (NASDAQ:OPCH) Given Consensus Rating of "Moderate Buy" by Brokerages

Key Points

• Option Care Health, Inc. has been rated a "Moderate Buy" by thirteen brokerages, with a price target average of $35.10 among analysts.
• Insiders acquired a total of 59,411 shares of Option Care Health stock in the last quarter, indicating increased confidence in the company.
• Institutional investors own an impressive 98.05% of Option Care Health's stock, showcasing strong backing from larger financial entities.

Shares of Option Care Health, Inc. (NASDAQ:OPCH - Get Free Report) have received an average recommendation of "Moderate Buy" from the thirteen brokerages that are covering the firm, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold rating and nine have issued a buy rating on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $35.10.

OPCH has been the subject of a number of research analyst reports. Weiss Ratings reiterated a "hold (c)" rating on shares of Option Care Health in a report on Wednesday, October 8th. Citigroup reiterated an "outperform" rating on shares of Option Care Health in a report on Thursday, July 31st. JMP Securities lifted their target price on Option Care Health from $36.00 to $38.00 and gave the stock a "market outperform" rating in a report on Thursday, July 31st. Morgan Stanley started coverage on Option Care Health in a report on Friday. They issued an "overweight" rating and a $35.00 target price for the company. Finally, Barrington Research restated an "outperform" rating and set a $38.00 price objective on shares of Option Care Health in a report on Tuesday, September 23rd.

Insider Activity

In other news, Director Norman L. Wright acquired 3,411 shares of the firm's stock in a transaction dated Tuesday, September 9th. The stock was purchased at an average price of $29.31 per share, for a total transaction of $99,976.41. Following the completion of the acquisition, the director directly owned 15,501 shares in the company, valued at $454,334.31. The trade was a 28.21% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Harry M. Jansen Kraemer, Jr. acquired 36,000 shares of the firm's stock in a transaction dated Wednesday, August 20th. The shares were purchased at an average price of $27.15 per share, with a total value of $977,400.00. Following the acquisition, the director owned 375,390 shares of the company's stock, valued at approximately $10,191,838.50. This represents a 10.61% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought a total of 59,411 shares of company stock worth $1,627,576 over the last quarter. 0.64% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Option Care Health

Several hedge funds and other institutional investors have recently modified their holdings of the company. Fort Washington Investment Advisors Inc. OH increased its holdings in shares of Option Care Health by 43.8% during the third quarter. Fort Washington Investment Advisors Inc. OH now owns 1,270,685 shares of the company's stock valued at $35,274,000 after acquiring an additional 387,281 shares in the last quarter. Blue Trust Inc. grew its holdings in Option Care Health by 31.0% during the third quarter. Blue Trust Inc. now owns 8,508 shares of the company's stock worth $236,000 after buying an additional 2,013 shares in the last quarter. Sheets Smith Wealth Management grew its holdings in Option Care Health by 3.6% during the third quarter. Sheets Smith Wealth Management now owns 25,841 shares of the company's stock worth $717,000 after buying an additional 903 shares in the last quarter. Pacer Advisors Inc. bought a new stake in Option Care Health during the third quarter worth $593,000. Finally, Brookstone Capital Management bought a new stake in Option Care Health during the third quarter worth $337,000. Institutional investors own 98.05% of the company's stock.

Option Care Health Price Performance

Option Care Health stock opened at $27.77 on Monday. The firm has a market cap of $4.51 billion, a P/E ratio of 22.22, a P/E/G ratio of 1.69 and a beta of 0.88. The stock's 50 day moving average is $28.01 and its 200 day moving average is $30.24. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.52 and a quick ratio of 1.00. Option Care Health has a one year low of $21.39 and a one year high of $35.53.

Option Care Health (NASDAQ:OPCH - Get Free Report) last issued its earnings results on Wednesday, July 30th. The company reported $0.41 earnings per share for the quarter, topping analysts' consensus estimates of $0.40 by $0.01. The business had revenue of $1.42 billion during the quarter, compared to the consensus estimate of $1.35 billion. Option Care Health had a return on equity of 17.53% and a net margin of 3.93%.The firm's revenue for the quarter was up 15.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.30 earnings per share. Option Care Health has set its FY 2025 guidance at 1.650-1.720 EPS. As a group, research analysts expect that Option Care Health will post 1.22 EPS for the current year.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.